Cytokines, Kinases, and Beyond: Advancing Next-generation Immunomodulatory Strategies and Precision Small-molecule Therapies in Autoimmune Disease

A BSTRACT Autoimmune diseases are a diverse group of chronic conditions characterized by the immune system mistakenly attacking the body’s tissues, with common examples including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. The immune system’s role in maintaining homeostasis is crucial, and its dysregulation leads to persistent inflammation and tissue damage in autoimmune disorders. Immunomodulatory agents, encompassing traditional immunosuppressants and novel targeted therapies, have transformed disease management by specifically modulating immune pathways rather than broadly suppressing immune function. Small molecules, in particular, offer advantages such as oral administration and the ability to target intracellular signaling, including kinases like Janus kinase (JAK), and have shown promise in both efficacy and safety. However, challenges remain regarding specificity and infection risk. Targeted cytokine inhibition, focusing on molecules such as interleukin-1 (IL-1), IL-6, and IL-17, has revolutionized treatment, with inhibitors demonstrating significant clinical benefits in rheumatoid arthritis and psoriasis. Modulation of immune cell signaling, including using JAK inhibitors and RORγt transcription factor inhibitors, directly impacts Th17 cell differentiation and inflammatory responses, offering new avenues for intervention. Ongoing research into pathways such as GMP-AMP synthase-stimulator of interferon gene, gasdermin D, and sphingosine 1-phosphate receptors, as well as innovations in precision medicine, aim to enhance the specificity and safety of small molecule therapies, paving the way for more personalized and effective treatments for autoimmune diseases.